Abstract: The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof, the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.

Abstract: A method for reducing skin sensitization of an asenapine-containing patch comprising a backing layer and an adhesive agent layer, the method comprising: using an adhesive agent for preparing the adhesive agent layer, the adhesive agent containing free asenapine in a range of 2 to 5% by mass, styrene-isoprene-styrene block copolymer (SIS) in a range of 7 to 18% by mass, polyisobutylene (PIB) in a range of 0.5 to 10% by mass, alicyclic saturated hydrocarbon resin in a range of 30 to 70% by mass, and liquid paraffin in a range of 5 to 10% by mass, relative to a total amount of the adhesive agent; and preparing the asenapine-containing patch whose average cumulative amount of skin permeation of asenapine (24 hours) after applying the asenapine-containing patch to skin of a dorsal scapular region of a 5-week-old Hartley white female guinea pig and holding the asenapine-containing patch with an occlusive dressing for 24 hours is in a range of 90 to 300 ?g/cm2 in terms of free form.

Abstract: The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof, and the adhesive agent layer further contains an alicyclic saturated hydrocarbon resin and at least one aliphatic alcohol selected from the group consisting of lauryl alcohol, octyldodecanol, oleyl alcohol, and myristyl alcohol.

Abstract: The present invention provides a patch comprising an adhesive layer on a backing, wherein the adhesive layer contains a adhesive base, a skin irritant drug or a pharmaceutically acceptable salt thereof, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0009 to 0.08% by mass based on the total mass of the adhesive layer.

Abstract: The present invention provides a rotigotine stabilization method for stabilizing rotigotine and/or a pharmaceutically acceptable salt thereof in a rotigotine-containing patch comprising a backing layer and an adhesive agent layer, the adhesive agent layer containing the rotigotine and/or the pharmaceutically acceptable salt thereof and a styrene-based thermoplastic elastomer, the method comprising further incorporating cross-linked polyvinylpyrrolidone in the adhesive agent layer in a content of 3 to 25% by mass in the adhesive agent layer.

Abstract: A method for reducing skin sensitization of an asenapine-containing patch comprising a backing layer and an adhesive agent layer, the method comprising: using an adhesive agent for preparing the adhesive agent layer, the adhesive agent comprising free asenapine in a range of 2 to 5% by mass, isopropyl palmitate in a range of 5 to 12% by mass, styrene-isoprene-styrene block copolymer in a range of 10 to 20% by mass, polyisobutylene in a range of 3 to 10% by mass, alicyclic saturated hydrocarbon resin in a range of 50 to 70% by mass, and liquid paraffin in a range of 5 to 12% by mass, relative to a total amount of the adhesive agent; and preparing the asenapine-containing patch having an amount of the adhesive agent layer after drying in a range of 100 to 400 g/m2.

Abstract: The present invention provides a patch comprising a backing, and an adhesive layer on the backing, wherein the adhesive layer contains at least one drug selected from the group consisting of oxybutynin and a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive base, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0007 to 0.05% by mass based on the total mass of the adhesive layer.

Abstract: The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof, the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.

Abstract: The present invention provides a patch comprising a backing, and an adhesive layer on the backing, wherein the adhesive layer contains at least one drug selected from the group consisting of oxybutynin and a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive base, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0007 to 0.05% by mass based on the total mass of the adhesive layer.

Abstract: An oxybutynin-containing transdermal absorption preparation includes a support layer that is formed of a base fabric and has water repellency in at least a part thereof, and an adhesive layer laminated on one side of the support layer, in which the adhesive layer includes an adhesive composition containing oxybutynin or a pharmaceutically acceptable salt thereof, cholesterols, and a rubber adhesive base. The oxybutynin may be oxybutynin hydrochloride. A portion having the water repellency may be formed by a fluorine-containing compound. The base fabric may be a knitted fabric.